UniQure stock surges after FDA U-turn clears path to gene therapy filing
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demandin...
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.